Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent.

Trial Profile

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery restenosis; Coronary disorders; Ischaemia; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms LONG-DES-III
  • Most Recent Events

    • 12 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 06 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top